1. Introduction {#sec1}
===============

In recent years, research on neurobiological risk factors for major depressive disorder (MDD) has increasingly identified neurobiological contributions to disease risk. This is important since MDD is one of the leading causes of years lost due to disability ([@ref61]) and is associated with high mortality rates ([@ref46]). One of the major methodological approaches in this domain has been neuroimaging. Several studies in patients reported functional as well as structural brain alterations ([@ref19]). Functional findings suggest dysregulation in neural circuits involving the prefrontal cortex as well as limbic structures (including the amygdala and hippocampus) ([@ref47]). In line with these findings are results from structural imaging: Meta-analyses have highlighted volume reductions in the bilateral anterior cingulate cortex (ACC), dorsomedial frontal cortex, right middle frontal gyrus extending into the precentral gyrus, bilateral putamen, caudate, and right anterior insula/inferior frontal cortex in MDD ([@ref9]). [@ref4] described volume reductions in the frontal, orbitofrontal and cingulate cortices, hippocampus and striatum. Yet, as has been shown in a review by [@ref27], some of these findings have been inconsistent, e.g., those concerning amygdala volumes. Diverging results might be due to methodological differences of study design and data analysis. Moreover, biological variables (e.g., age and sex) as well as psychopathological factors (e.g., age of onset, course of the disease and medication) might contribute to inconsistent findings ([@ref4]). Even given widespread and replicable structural--functional alterations in patients compared to controls, it remains unclear whether such changes occur after the manifestation of MDD symptoms, whether they represent risk factors for the development of MDD, or whether they are related to confounds such as comorbidity, medication use, social stress and lifestyle changes associated with having a severe mental illness.

Research on etiology of MDD has shown that multiple factors contribute to the manifestation of the disorder. MDD etiology is linked to interactions between genetic vulnerability -- indexed not only by familial liability, but also by heritable traits such as neuroticism -- and biographical/ environmental factors such as adverse life events ([@ref10]). Often, risk factors are combined. For instance, patients with a family history of depression show a lower age of onset and are more likely to have recurrent depressive phases ([@ref34]). With an overall heritability of 30--40%, MDD is less strongly genetically determined than other severe mental illnesses, which emphasizes the importance of gene--environment interactions. One strategy to disentangle the complex network of influencing factors is to focus on high-risk subjects for MDD. Healthy first-degree relatives of MDD patients (H1^st^R) enable the investigation of vulnerability factors as well as resilience markers related to heritable or shared environmental (e.g., early familial) factors. While vulnerability factors are thought to increase risk of mental illness, resilience factors are considered to facilitate healthy functioning. Applied to quantitative, more biologically based measures such as neuroimaging, these studies add to the search for intermediate (or "endo"-) phenotypes. One necessary, but by no means sufficient, criterion for an endophenotype is that markers found in affected family members should also be found in nonaffected family members at a rate higher than that of the general population ([@ref31]). Conversely, findings opposite in directionality between patients and their family members in similar systems may point to resilience factors protecting healthy relatives from manifest illness despite their genetic susceptibility. In the domain of brain structure, few manual tracing and voxel-based morphometry (VBM) studies searching for MDD endophenotypes have been published to date. Manual tracing studies revealed smaller hippocampal but larger amygdala volume in high-risk subjects ([@ref8]; [@ref48]; [@ref51]). The reduction in hippocampal volume in high-risk subjects compared to healthy controls or MDD patients was confirmed by VBM ([@ref1]; [@ref7]; [@ref11]; [@ref12]; [@ref17]). Furthermore, VBM studies exhibited a reduction in local gray matter in the dorsolateral prefrontal cortex (DLPFC) ([@ref1]; [@ref11]). Nevertheless, the explanatory power of previous results regarding the potential structural endophenotypes of MDD is limited due to heterogeneity in sample sizes, studied risk populations and applied methods, e.g. region-of-interest (ROI) based analyses only.

To advance the data available in this field, we collected structural magnetic resonance imaging (MRI) data from a large sample of H1^st^R and matched healthy control subjects without any familial history of psychiatric illness (HC) and conducted a whole-brain VBM-analysis, thereby applying a very conservative statistical threshold. For consistency with the literature, we additionally tested our data for effects in regions previously observed using small volume alpha error adjustment. This approach decreases the probability of false positive as well as false negative findings and provides new insights in brain structural correlates linked to the genetic risk for MDD.

2. Methods and materials {#sec2}
========================

2.1. Participants {#sec2.1}
-----------------

All subjects were enrolled in a multicenter study ([@ref22]) conducted by the Charité --- Universitätsmedizin Berlin, the Universitätsklinikum Bonn and the Zentralinstitut für Seelische Gesundheit, Mannheim. The study was performed in accordance with the latest version of the Declaration of Helsinki and approved by the local Ethics Committees. Subjects participated in the study after providing written informed consent. 63 H1^st^R (38 females; 21 subjects from Berlin, 21 from Bonn and 21 from Mannheim) were measured and 63 HC (38 females; 21 subjects from Berlin, 21 from Bonn and 21 from Mannheim) matched for age and sex were taken from a larger study sample. Affected relatives of the H1^st^R group (43 offspring, 17 siblings, 1 parent, 2 NA) were examined by an experienced psychiatrist or clinical psychologist using the German version of the Structured Clinical Interview for DSM-IV (SCID-I) ([@ref23]) or had to provide a medical report confirming a major depressive disorder. Both the H1^st^R and the HC group had no history of any neurological disorder or lifetime psychiatric axis I disorder including drug or alcohol dependence as verified by an interview according to the Screening Interview for DSM-IV axis I disorders. Further, subjects in the HC group were questioned carefully whether there is any knowledge about psychiatric disorders in their family, and special emphasis was put on first degree relatives. Subjects with axis 1 disorders or unclear diagnoses in their families were not included in the study sample. Handedness was measured by the Edinburgh Handedness Inventory ([@ref45]) (H1^st^R: 55 right handers, 6 left handers, 2 both hander; HC: 57 right handers, 4 left handers, 2 both hander). In addition, years of education and premorbid intelligence assessed by the multiple choice verbal intelligence test (MWT-B) ([@ref39]) as well as clinical scales such as the Symptom Check List (SCL-90-R) with the subscales Global Severity Index (SCL-GSI) and Depression (SCL-Depr) ([@ref18]) were assessed. No significant difference between the two groups were found (see [Table 1](#tbl1){ref-type="table"}). Furthermore, a composite score (NegAff) comprising three self-report measures associated with the experience of negative affect was included, in detail: 1) the trait form of the Spielberger State/Trait Anxiety Inventory (STAI) ([@ref53]) for the assessment of feelings of tension, fear and worry; 2) the neuroticism scale from the NEO five-factor inventory ([@ref14]) which assesses the degree to which an individual experiences negative affects such as anger, sadness and guilt; and 3) the harm avoidance scale of the Temperament and Character Inventory (TCI) ([@ref13]) which measures a personality trait characterized by anticipatory worry, pessimism, easy fatigue and shyness. The composite score was calculated by using the average of the *Z*-scores for each individual scale as suggested previously ([@ref35]). The two groups did not differ on this scale either.

2.2. Statistical analysis of sociodemographical, psychometrical and clinical data {#sec2.2}
---------------------------------------------------------------------------------

Statistical analyses were performed using the software package MATLAB (MATLAB 7.8, The MathWorks Inc., Natick, MA, 2009). Due to violation of statistical assumptions for parametrical testing (normal distribution as assessed by the Kolmogorov--Smirnov test or the level of measurement), the medians of age, years of education, IQ, SCL-GSI and SCL-Depr and the composite score NegAff were tested regarding group differences via non-parametrical Wilcoxon rank-sum test (see [Supplementary Table S1](#sm1){ref-type="sec"}).

2.3. MRI acquisition {#sec2.3}
--------------------

Structural MRI data were acquired on a 3 Tesla Siemens MAGNETOM Tim Trio MRI system (Siemens, Erlangen, Germany) at all three study sites. All subjects underwent a T1-weighted three-dimensional magnetization prepared rapid gradient echo (MP-RAGE) sequence with an isotropic spatial resolution of 1 mm^3^ (repetition time = 1.57 s, echo time = 2.74 ms, flip angle = 15°). Additional quality control measurements via EPI sequences were conducted at all study sites on every day of data collection according to a multicenter quality assurance protocol ([@ref24]), revealing stable signals over time and comparable quality between sites.

2.4. Voxel-based morphometry (VBM) {#sec2.4}
----------------------------------

MRI data processing was performed according to an established voxel-based morphometry protocol using the VBM8 toolbox (Structural Brain Mapping Group, University of Jena, Germany; [[http://dbm.neuro.uni-jena.de/vbm8]{.ul}](http://dbm.neuro.uni-jena.de/vbm8){#inter-ref001}) for the Statistical Parametric Mapping 8 Software (SPM8, Welcome Trust Centre for Neuroimaging, UCL, London, UK; [[http://www.fil.ion.ucl.ac.uk/spm]{.ul}](http://www.fil.ion.ucl.ac.uk/spm){#inter-ref002}).

Before segmentation into tissue classes, images were visually inspected to remove images with artefacts, manually aligned to the orientation as defined by the used brain templates, and the origin was set on the anterior commissure. Afterwards, individual anatomical images were classified into gray matter, white matter and cerebro-spinal fluid as well as three extra-cerebral tissue classes and transformed to the stereotactical standard space as provided by the International Consortium for Brain Mapping (6 tissue class template; [[http://www.loni.usc.edu/ICBM]{.ul}](http://www.loni.usc.edu/ICBM){#inter-ref003}) using the diffeomorphic image registration algorithm (DARTEL) developed by [@ref6]. To account for the local normalization degree, gray matter images were modulated with the nonlinear transformation parameters as computed during the normalization procedures. The resulting images contain the volume proportion of probabilistically assigned gray matter tissue for each voxel. These gray matter tissue probability images were again inspected visually and finally smoothed using an isotropic Gaussian kernel with a full-width at a half-maximum of 8 mm. Note that each image of the regional GM volume was corrected for individual brain size, since this step is part of the VBM8 toolbox routine.

A voxel-wise whole-brain 2 × 3 analysis of covariance (ANCOVA) with the factor of interest Group (H1^st^R vs. HC) was performed. The additional factor scanner site allowed for detailed quality control regarding possible influences of the multicenter setting: no interaction between the two factors was observed (*p* \< .05 FWE corr.). Due to its impact on brain volume, sex and the MWT-B were also used as covariates. Finally, age was included as covariate of no interest. Only findings that passed a significance level of *p* \< .05 (voxel level inference), whole-brain family wise error (FWE) corrected for multiple comparison and a cluster size of at least 10 adjacent voxels, are reported. Gray matter regions that showed a significant group effect were anatomically labeled using the probabilistic cytoarchitectonic Anatomy toolbox ([@ref21]) as implemented in SPM8. Based on the maps provided by [@ref2] (amygdala and hippocampus), the cytoarchitectonic probabilities for these regions were computed. To test for the direction of differences in gray matter volume, we applied post hoc*t*-tests at the peak voxel positions for the individual gray matter values.

Due to our strong hypotheses based on previous literature, we performed an adjustment of alpha error probabilities for the volumes of the following *a-priori* defined anatomical regions as provided by the Automated Anatomical Labelling (AAL) ([@ref57]) brain atlas: bilateral hippocampus (volume: right 7.6 cm^3^, left 7.5 cm^3^), amygdala (volume: right 1.9 cm^3^, left 1.7 cm^3^) and DLPFC (?? middle frontal gyrus; Brodmann areas 8, 9, 46; volume: right 37.9 cm^3^, left 38.6 cm^3^) (see [Supplementary Fig. S1](#sm1){ref-type="sec"}). Only results with an adjusted alpha error probability less than .05 family-wise error (FWE) corrected for multiple comparisons are reported.

In order to probe whether differences in gray matter volume between H1^st^R and HC relate to subclinical depressive symptoms and experience of negative affect, we conducted, for both groups, voxel-wise correlation analyses (non-normally distributed: Spearman\'s rho, corrected for age, sex and MWT-B) for the self-report measure SCL-Depr as well as the NegAff and local gray matter volume in the ROIs.

3. Results {#sec3}
==========

3.1. Sociodemographical, psychometrical and clinical sample characteristics {#sec3.1}
---------------------------------------------------------------------------

For results of sociodemographical, psychometrical and clinical data, see [Table 1](#tbl1){ref-type="table"}.

3.2. Voxel-wise local gray matter volume --- whole-brain analysis {#sec3.2}
-----------------------------------------------------------------

VBM results revealed a main effect of Group for the amygdala bilateral with larger local gray matter volume for H1^st^R subjects in the bilateral amygdala (left: *x* = -21, *y*= 2, *z*= -14, 278 voxels; right: *x*= 26, *y*= 0, *z*= -15, 318 voxels) compared with HC subjects (see [Fig. 1](#fig1){ref-type="fig"}and [Supplementary Table S2](#sm1){ref-type="sec"}). In contrast, HC did not have any relative increases in local gray matter volume.

3.3. Voxel-wise local gray matter volume --- ROI based analyses {#sec3.3}
---------------------------------------------------------------

Alpha error adjustment for a-priori defined ROIs revealed a larger local gray matter volume for H1^st^R subjects in the bilateral hippocampus, bilateral amygdala and left DLPFC (see [Table 2](#tbl2){ref-type="table"}).

3.4. Correlation analysis {#sec3.4}
-------------------------

Correlation analysis revealed a significant positive correlation between NegAff score and local gray matter volume in the left (Spearman\'s rho = .43, *p*\< .001) and right DLPFC (Spearman\'s rho = .458, *p*\< .001) in the H1^st^R group (see [Fig. 2](#fig2){ref-type="fig"}). Furthermore, a trend-wise positive correlation between the SCL-Depr score and local gray matter volume in the right hippocampus (Spearman\'s rho = .23, *p*= .074) and left amygdala (Spearman\'s rho = .206, *p* = .102) has been observed. For HC subjects, no significant correlation was found.

4. Discussion {#sec4}
=============

The main findings of our study are larger local gray matter volumes in the bilateral amygdala in healthy relatives of MDD patients compared to control subjects. With a statistically highly conservative approach (whole-brain analysis FWE corrected for multiple comparisons) this study proves brain volume differences in high-risk subjects. According to the literature, the evidence for volumetric differences in limbic regions is inconsistent in MDD patients ([@ref9]). While one study in pediatric MDD ([@ref50]) as well as a meta-analysis of VBM results in first-episode MDD patients ([@ref9]) showed relatively reduced local gray matter volume in the amygdala, larger amygdala volume has also been shown in samples of medicated MDD patients ([@ref33]; [@ref42]) as well as in early stages of MDD ([@ref26; @ref25]; [@ref38]; [@ref58]). In contrast, previous studies in high-risk subjects consistently reported a larger volume in the amygdala ([@ref8]; [@ref51]), which is in line with our findings. Further, it is of high interest that recent studies also linked larger amygdala volume with psychological characteristics of depression, in terms of heightened negative affect ([@ref35]) and negative memory bias ([@ref28]), even in non-depressed subjects. These aspects are considered to be important vulnerability factors, e.g. frequent experience of 'negative emotionality' such as anxiety, low mood, and hostility is characteristic of the personality trait of neuroticism which is a well-known risk factor for MDD ([@ref36]; [@ref54]). In line with these findings, it has been shown that unaffected twins of MDD patients have an increased tendency to display negative affect in response to minor stressors in daily life ([@ref60]) and show higher stress sensitivity ([@ref59]) and that unaffected relatives differ from the standard population in terms of neural correlates of inhibition of negative emotional information ([@ref40]). Albeit the present study did not find any significant relationship between amygdala volume and experience of negative affect and only a trend-wise relation to subclinical depressive symptoms, we found a significant positive correlation of the experience of negative affect and bilateral DLPFC volume in the H1^st^R group, which was not present in the HC subjects.

In non-human primates, larger DLPFC volume and thickness were related to resilience to stress exposure, which in turn has been linked to emotional competences in humans ([@ref62]). Considering the close functional relationship between the DLPFC and amygdala, it is of interest that also on a functional level the DLPFC has been well-documented to be involved in emotion regulation in terms of showing increased activity during, e.g. reappraisal of negative events and suppression of negative memories ([@ref29]). Thus, the amygdala--prefrontal cortex circuitry is central to the emotional processing of biologically salient stimuli, memory formation and response regulation ([@ref37]), important functions that are altered in MDD ([@ref32]; [@ref49]). Further, fMRI studies showed that the functional relationship between the amygdala and the DLPFC is decreased in depression ([@ref3]; [@ref15]; [@ref52]). Thus, the larger gray matter volume in the amygdalae and the correlation between DLPFC gray matter volume and the experience of negative affect might be provoked by more intense affective processes in the amygdala as well as more demanding top down regulation of these processes by the DLPFC. Taking the findings together, we conclude that the found structural brain differences in the amygdala might reflect an increased vulnerability for the onset of MDD in healthy first-degree relatives. To further understand the role of the amygdala in the etiology of depression, non-MR-related findings should also be taken into account, like post-mortem neuromorphometric and histopathological investigations ([@ref43]).

Additionally, our region-of-interest analyses methodologically followed previous studies in this field and identified altered gray matter volumes in relatives of MDD patients in regions also highlighted by previous work: earlier studies found group differences in the amygdala ([@ref8]; [@ref51]), the hippocampus ([@ref1]; [@ref7]; [@ref11]; [@ref12]; [@ref17]; [@ref48]) and the DLPFC ([@ref1]; [@ref11]) by means of region of interest VBM analyses and manual tracing methods respectively. However, whereas a larger amygdala volume in our H1^st^R participants is in line with previous studies ([@ref8]; [@ref51]), we also found larger volume in the hippocampus as well as the DLPFC which is in contrast to the previous literature. Given the methodological differences in sample size and sample characteristics, like the definition of high-risk, further studies have to specify the direction and the precise role of DLPFC and hippocampal volume in MDD etiology. On the one hand, reduced hippocampal volumes were determined in subjects with different risk factors related to depression ([@ref12]; [@ref16]; [@ref55]). On the other hand, pointing to state-dependent effects, reduced hippocampal volumes can be abolished by antidepressant treatment ([@ref5]; [@ref44]; [@ref56]).

Limitations of our study arise from the question of how structural alterations influence brain function in terms of modulating the probability of MDD in high-risk populations. In this context, it is worthy to mention that the detailed relationship between altered brain structure and its function is not fully understood, i.e. changes in local gray matter volume might be due to various processes. For example, heightened gray matter volume as described might point to a more ineffective functional state in the respective brain system. Evidence from animal studies points to a variability in local gray matter volume in amygdalar nuclei related to neuropathic pain and depressive symptoms ([@ref30]). Further, volumetric changes might also be related to neurochemical alterations, as discussed for MDD --- like GABAergic deficits ([@ref41]), which were also linked to chronic deficits in neurotrophic support in mice models ([@ref20]). Further, we conducted a cross-sectional analysis. Longitudinal analyses assessing brain volume before and after illness onset are needed to underline the importance of neurobiological markers of vulnerability for MDD. Moreover, we do not know whether the studied high-risk subjects are indeed carriers of genetic risk factors for MDD. H1^st^R share approximately 50% of common genetic variants related to the disorder with their affected family members, in addition to a degree of shared early environment. Of course we cannot determine which specific variants the studied high-risk subjects carry, given the limited number of genome-wide supported variants associated with MDD, as well as we do not know the specific ratio within our group of H1^st^R subjects which develop a major depressive episode in the future. Since MDD does manifest over the whole lifespan, it is also not possible to reliably estimate the probability of MDD manifestation in the studied sample. However, the close degree of kinship of our H1^st^R subjects to the affected family members suggests a high level of genetic similarity with the MDD relatives.

Besides these limitations, the strengths of this study include the fact that it was conducted on a representative sample of 63 subjects per group and is therefore less likely to be affected by biases associated with convenience sampling or clinical populations, which is also an important advantage of the used high-risk approach. We advanced evidence in this field by applying very conservative statistical thresholds and reporting whole brain FWE-corrected results as well as followed former research strategies by replicating previous studies. Thus, it is very likely that the observed larger volume in the amygdalae in healthy H1^st^R subjects is a reliable and valid finding and may represent a vulnerability factor for developing MDD. At this point, future research has to replicate whether volumetric alterations depict an endophenotype for MDD.
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Supplementary materials for Larger amygdala volume in first-degree relatives of patients with major depression.
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![Whole-brain FWE correctable results. Middle panel: Clusters with a significant main effect of group. Left and right panels: Box plots for local gray matter volumes of H1^st^R (*n* = 63) and HC (*n*= 63) at peak voxel coordinates. The dots indicate the individual gray matter volumes. Abbreviation: CI --- confidence interval; H1^st^R --- healthy first-degree relatives of MDD patients; HC --- healthy control subjects.](gr1){#fig1}

![Correlation between SCL depression score and local gray matter volume in the left amygdala and right hippocampus as well as the negative affect composite score and bilateral DLPFC volume in H1^st^R (*n*= 63). Scatter plots between individual SCL --- depression or negative affect score and gray matter volume at peak coordinate are shown. Additionally the post-hoc regression model (*solid line*) and its 95% confidence interval (*dotted lines*) are displayed. Abbreviations: *r*~s~ -- Spearman\'s rho; DLPFC --- dorsolateral prefrontal cortex; Amyg --- amygdala, Hippo --- hippocampus.](gr2){#fig2}

###### 

Sociodemographical and clinical data. Abbreviations: H1^st^R --- healthy first-degree relatives of MDD patients; HC --- healthy control subjects; MWT-B --- multiple choice verbal intelligence test; SCL-90-R --- Symptom Check List; GSI --- Global Severity Index, \*IQ.

  ----------------------------------------------------------------------------------------------------------------------
  Variable                                          H1^st^R\      HC\           Wilcoxon                          
                                                    (25 ?/38 ?)   (25 ?/38 ?)                                     
  ------------------------------------------------- ------------- ------------- ------------ ----------- -------- ------
  Age in years\                                     25.0          10.4/39.6     26.0         11.2/40.8   --.14    .89

  Years of education\                               15.5          10.8/20.2     15.5         11.7/19.3   --.54    .588

  MWT-B\                                            30 (107\*)    20.5/39.5     30 (107\*)   25.1/34.9   --.76    .45

  SCL-90-R (GSI)\                                   .16           --.18/.5      .12          --.2/.5     --1.32   .19

  SCL-90-R (depression)\                            .15           --.5/0.8      .08          --.4/0.6    --1.28   .202

  Composite score: experience of negative affect\   --.19         --1.9/1.5     --.18        --1.9/1.6   --.04    .965
  ----------------------------------------------------------------------------------------------------------------------

###### 

Differences in local gray matter volume between H1^st^R (*n*= 63) and HC (*n* = 63) subjects (alpha error probabilities adjusted for a-priori regions of interest). Abbreviations: CP --- cytoarchitectonic probability, H --- hemisphere; DLPFC --- dorsolateral prefrontal cortex; SF --- superficial group; CA --- cornu ammonis.

  --------------------------------------------------------------------------------------------------------
  Brain structure (CP)   H   Cluster size   Z (peak)   T (peak)   p (FWE)   MNI coord. (mm)         
  ---------------------- --- -------------- ---------- ---------- --------- ----------------- ----- ------
  Amygdala (SF)\         L   389            5.67       6.10       \<.001    --21              2     --14

  Amygdala (SF)\         R   379            5.42       5.80       \<.001    26                0     --15

  DLPFC\                 L   97             3.89       4.03       0.026     --32              47    28

  Hippocampus (CA)       L   480            4.47       4.68       0.001     --26              --6   --17

  Hippocampus (CA)       R   367            4.96       5.25       \<.001    27                --4   --17
  --------------------------------------------------------------------------------------------------------
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